We investigated whether polymorphisms in genes associated with HIV disease progression and/or immune activation affect CD4(+) T-cell recovery in HIV patients who began combination anti-retroviral therapy (ART) with advanced immunodeficiency and achieved stable control of plasma viremia. Patients with CD4(+) T-cell Counts < 300 cells/mu L (n = 33) and > 400 cells/mu L (n = 37) oil ART were compared. A multiple case-control logistic regression associated carriage of BATI (1,2) or interleukin (IL)6-174(2,2) with low CD4(+) T-cell Counts (P = 0.012). BATI*2 uniquely marks the central major histocompatibility complex region of a conserved haplotype (HLA-A1,B8,BAT1*2,TNFA-308*2,DR3,DQ2). There was no association between alleles carried at CCR5 Delta 32, CCR5 59029, CCR5 59353, CCR2+190 (V641), SDFI 3'UTR, ILIA+4845, ILIB+3953, IL-4589, IL10-592, IL10-RI+536, IL10-RI+1112 IL12B 3'UTR, TNFA-308, or TNFA-1031 and CD4(+) T-cell Counts. We Suggest that immune activation and/or CD4(+) T-cell apoptosis in HIV patients oil effective ART is influenced by genetic factors.
|Journal||JAIDS: Journal of Acquired Immune Deficiency Syndromes|
|Publication status||Published - 2006|